Well Health Technologies ($WELL.TO) FINS Review
Q2 2025
If you’re familiar with my work, then you know that I have had a bit of a love/hate relationship with Well Technologies.
My overall frustrations with the company can best be summed up by the attached article I wrote about them a little over a year ago.
Importance of Well Health's Upcoming Q2 & Q3 Results
Bull. Bear. Long. Swing trader. I’ve been all of them when it comes to Well Health Technologies over the past several years. I do hold a position currently, but I’m not sure how I would define the st…
There is some irony in the fact that the stock is only two cents higher today than it was when I wrote that piece on July 26th of last year - $4.78 currently, but has seen the stock go as high as $7.36, and as low as $3.72. (note I started this article on the weekend).
I ignored the stock when it was $7, but became much more interested when it dipped below four bucks back in April. Since then I have called out two buy zones above $3.72 and $4.50 support levels. I’ve bought the stock in each of those zones.
In true Well Health fashion, upon announcing their earnings, the stock rose by 7% in early trading, but finished the day down 6.5%. Sadly, this is not unusual.
I have some theories as to why this seems to be a regular occurrence, and it’s something that I discussed in length in that article mentioned earlier. Well Health writes great headlines, produces great PowerPoint slides and there isn’t an “Adjusted” number that the company doesn’t like. And when necessary, the company will just invent their own metrics like FCFA2S (Free Cash Flow Available to Shareholders).
Therefore the headlines are typically better than the actual meat and potato metrics that astute investors typically look at. I think swing traders have become accustomed to this, so they buy leading into earnings and then sell the news. Now I will admit that I haven’t fully picked apart the details in this set of financials to determine if the above is indeed the case. Let’s rectify that now.
Note, I did not review Well’s Q1 but their 2024 annual filings received a three star rating which was unchanged.
The good news is that by Tuesday morning, the stock is now above $5 again and looks to be holding $4.98 support, potentially setting up a third Wolf Buy Zone.